Greenwich LifeSciences Set to Join Russell 2000 Index Again
June 26, 2024 07:33 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Nordicus Partners Corporation Enters Into A Consultancy Agreement With BIO-CONVERT In Denmark
June 21, 2024 14:37 ET
|
Nordicus Partners Corporation
Beverly Hills, California., June 21, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing...
Greenwich LifeSciences Announces $2.5 Million Private Placement
June 14, 2024 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III...
CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials
June 11, 2024 09:00 ET
|
CanaQuest Medical Corp.
Appointee, formerly with GW Pharma (subsidiary), brings extensive expertise in cannabinoid therapeutics, including the FDA-approved launch of cannabidiol (Epidiolex®) TORONTO, ON, June 11, 2024 ...
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
June 11, 2024 08:20 ET
|
Processa Pharmaceuticals, Inc.
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses...
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
May 20, 2024 08:45 ET
|
GRI Bio, Inc.
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score...
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 14, 2024 16:05 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery...
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
May 06, 2024 11:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
May 06, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
May 01, 2024 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with...